A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MCL / mantle cell lymphoma

[Related PubMed/MEDLINE]
Total Number of Papers: 2081
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MCL  (>> Co-occurring Abbreviation)
Long Form:   mantle cell lymphoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 18F-FDG PET or PET/CT in Mantle Cell Lymphoma. ---
2020 25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma. AUC, CI, HR, NHL, OS, PFS, ROC
2020 A case report of mantle cell lymphoma presenting as intussuscepting colon mass. CT, GI
2020 A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. ASCT, NHL, OS, PFS, R/R, RIT
2020 Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. cMCL, CNAs
2020 An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. BTK, RR
2020 An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process. FISH, NGS
2020 Application of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in mantle cell lymphoma. CT, F-FDG, Hgb, IPI
2020 Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. ATM
10  2020 Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. ASCT, BeEAM, LYSA, PFS
11  2020 Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. BC, MRD, PFS
12  2020 BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. BCR, BLNK, BRD4, IKZF3, PAX5
13  2020 Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45+CD19- cells but in the ALDHhigh Cells. ALDH, CSCs, DLBCL
14  2020 Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study. AIHA, AIHA/NHL, AITL, BCL-U, BMB, BMS, CLL/SLL, LBMI, MZBL, NHL
15  2020 Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. ---
16  2020 Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. NHL
17  2020 Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study. CCI, CIs, HR, HRs
18  2020 Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma; Small Cell Variant: A Real Diagnostic Challenge. Case Presentation and Review of Literature. CLL/SLL, FISH
19  2020 Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Bcl-2, MCL1, MZL, PI3K
20  2020 Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. DLBCL, FL, MM, NHL, OS, R/R
21  2020 Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma. BTK, IBN
22  2020 Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. BQR, ddPCR, MFC, MRD, qPCR
23  2020 E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells. ---
24  2020 Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis CI, HR, ORR, OS, PFS, SAEs
25  2020 Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. BTKi, CR, WES
26  2020 Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. cMCL, IHC, nnMCL, RT-qPCR
27  2020 Identification of key gene modules and hub genes of human mantle cell lymphoma by coexpression network analysis. GO, KEGG, WGCNA
28  2020 Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma. IgVH
29  2020 JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). ---
30  2020 LncRNA MORT Inhibits Cancer Cell Proliferation and Promotes Apoptosis in Mantle Cell Lymphoma by Upregulating miRNA-16. MORT
31  2020 Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). ---
32  2020 Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. R/R
33  2020 Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience. auto-SCT
34  2020 MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. HMG, NHL, PBMCs
35  2020 Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma. ---
36  2020 MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. DHL, EC, MYC-R, NL, OS
37  2020 Novel agents for mantle cell lymphoma: molecular rational and clinical data. NHL
38  2020 Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. BTK
39  2020 Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status. DLBCL, EBV, HPV, ISH, NHL, PTCL-NOS, PUMCH
40  2020 Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. 18F-FDG PET, auto-HSCT, ePET, HR, iPET, OS, PFS
41  2020 Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. ---
42  2020 Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma. BTZ, MM
43  2020 Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. ASCT, DFCI, MRD, RB, RC, WUSTL
44  2020 Sphingosine Kinase Blockade Leads to Increased Natural Killer T Cell Responses to Mantle Cell Lymphoma. NKT, S1P, SK1
45  2020 Stabilization of beta-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. BCR
46  2020 Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. MM, RI
47  2020 Systematic literature review of the global burden of illness of mantle cell lymphoma. ---
48  2020 Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. ALSG, HSCT
49  2020 Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. OS, R-CHOP, R-FC
50  2020 Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. 5'-UTRs, CCND1, MM
51  2020 Zanubrutinib: First Approval. BTK, ORR
52  2020 [Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance]. FISH, MEF2B
53  2020 [Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review]. BCR, CLL, NHL
54  2020 [Sequential development of mantle cell lymphoma following chronic lymphocytic leukemia]. CLL, RS
55  2019 A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients. IGHV
56  2019 A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. ASCT, BuMel, ORRs, OS, PFS
57  2019 A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. HDACs
58  2019 A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. BTK
59  2019 A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. ADC, AEs, CR, DLBCL, NHL, PBD, PRs, R/R
60  2019 A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. DLT, pG1
61  2019 A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient. DIs, HD-MTX, PK
62  2019 A Rare Manifestation of a Rare Disease: Mantle Cell Lymphoma Presenting With Aseptic Meningitis. ---
63  2019 Acalabrutinib for adults with mantle cell lymphoma. BTK, OS, R/R
64  2019 Acalabrutinib for mantle cell lymphoma. ---
65  2019 Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine-needle aspiration biopsy. FNAB, HPI
66  2019 Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. ---
67  2019 Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. AEs, BR, RCHOP
68  2019 Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. allo-HCT, CI, GVHD, NRM, OS, PFS
69  2019 Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. allo-SCT, GVHD, PFS
70  2019 An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. CI, FL, LPL/WM, MZL, PFS, Syk
71  2019 Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. BL, DLBCL, NHL, VEGFR2
72  2019 Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. DQ, DW, eCRFs
73  2019 Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. R-CHOP
74  2019 Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma. Hb, HR, LDH, OS, PFS, RDW, sMIPI
75  2019 ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. OS, PFS
76  2019 Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report. MTX, NHL, UBM
77  2019 Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass. ---
78  2019 Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. IVIVC, P-PSD, PBPK
79  2019 Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. BTK
80  2019 Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions. BTK
81  2019 Bruton Tyrosine Kinase Inhibitors: Present and Future. BTK, BTKis, CLL
82  2019 Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). BTK, CLL
83  2019 Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts? AMC, B2-MG, MIPI, NLR, OS, PFS, PLR, ROC
84  2019 CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. FISH
85  2019 CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. ---
86  2019 CD5-negative chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with gastrointestinal mantle cell lymphoma: an unusual case report. CLL/SLL
87  2019 CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. CD5, CD5, OS, PFS
88  2019 Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. CAR, scFv
89  2019 CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation. AUC, circ, lnc, mi, ROC
90  2019 Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy. PCA, S-FTIR
91  2019 Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. ---
92  2019 Clinical management of mantle cell lymphoma in the elderly. ---
93  2019 Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. allo-HSCT, MIPI, OS, PFS
94  2019 Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. B-NHL, CMV, DEX, RR
95  2019 Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. CI, HR, SEER
96  2019 Complete Endoscopic and Histopathological Remission of Mantle Cell Lymphoma of the Gastrointestinal Tract. GI, NHL, R-CVP
97  2019 Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review. CNS
98  2019 Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. CLL, DLBCL, FL, HCL, MZL, SDRPBL
99  2019 Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. ---
100  2019 CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. ---